DE69411584D1 - Isoxazoline derivate anwendbar als fibrinogen rezeptor antagonisten - Google Patents

Isoxazoline derivate anwendbar als fibrinogen rezeptor antagonisten

Info

Publication number
DE69411584D1
DE69411584D1 DE69411584T DE69411584T DE69411584D1 DE 69411584 D1 DE69411584 D1 DE 69411584D1 DE 69411584 T DE69411584 T DE 69411584T DE 69411584 T DE69411584 T DE 69411584T DE 69411584 D1 DE69411584 D1 DE 69411584D1
Authority
DE
Germany
Prior art keywords
fibrinogen receptor
receptor antagonists
compounds
isoxazoline derivatives
derivatives applicable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69411584T
Other languages
English (en)
Other versions
DE69411584T2 (de
Inventor
John Wityak
Thais Sielecki-Dzurdz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/304,614 external-priority patent/US5446056A/en
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Application granted granted Critical
Publication of DE69411584D1 publication Critical patent/DE69411584D1/de
Publication of DE69411584T2 publication Critical patent/DE69411584T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE69411584T 1993-11-24 1994-11-14 Isoxazoline derivate anwendbar als fibrinogen rezeptor antagonisten Expired - Fee Related DE69411584T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15785193A 1993-11-24 1993-11-24
US08/304,614 US5446056A (en) 1993-11-24 1994-09-12 Isoxazoline compounds useful as fibrinogen receptor antagonists
PCT/US1994/013153 WO1995014682A1 (en) 1993-11-24 1994-11-14 Isoxazoline compounds useful as fibrinogen receptor antagonists

Publications (2)

Publication Number Publication Date
DE69411584D1 true DE69411584D1 (de) 1998-08-13
DE69411584T2 DE69411584T2 (de) 1998-12-17

Family

ID=26854532

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69411584T Expired - Fee Related DE69411584T2 (de) 1993-11-24 1994-11-14 Isoxazoline derivate anwendbar als fibrinogen rezeptor antagonisten

Country Status (10)

Country Link
EP (1) EP0730589B1 (de)
JP (1) JPH09505589A (de)
AT (1) ATE168106T1 (de)
AU (1) AU677481B2 (de)
CA (1) CA2174415A1 (de)
DE (1) DE69411584T2 (de)
DK (1) DK0730589T3 (de)
ES (1) ES2120713T3 (de)
NZ (1) NZ276631A (de)
WO (1) WO1995014682A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
IL118007A0 (en) * 1995-05-24 1996-08-04 Du Pont Merck Pharma Isoxazoline compounds pharmaceutical compositions containing them and their use
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
US5939418A (en) * 1995-12-21 1999-08-17 The Dupont Merck Pharmaceutical Company Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
DE69632548T2 (de) * 1995-12-21 2005-06-02 Bristol-Myers Squibb Pharma Co. ISOXAZOLIN, ISOTHIAZOLIN UND PYRAZOLIN ALS FAKTOR Xa INHIBITOREN
ZA972195B (en) * 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
WO1997033887A1 (en) * 1996-03-15 1997-09-18 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
WO1998006707A1 (en) * 1996-08-15 1998-02-19 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
WO1998008840A1 (en) * 1996-08-29 1998-03-05 Merck & Co., Inc. Integrin antagonists
US6214834B1 (en) 1997-03-28 2001-04-10 Dupont Pharmaceuticals Company Integrin inhibitor prodrugs
US7109326B2 (en) 1997-04-15 2006-09-19 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
BR9810151A (pt) 1997-06-19 2000-08-08 Du Pont Pharm Co Composto, composição farmacêutica e método para tratamento ou prevenção de uma desordem tromoboembólica
ZA988735B (en) 1997-10-06 2000-03-23 Du Pont Pharm Co An efficient method for the conversion of nitriles to amidines.
DE69920888T2 (de) 1998-03-27 2006-02-02 Bristol-Myers Squibb Pharma Co. Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren
WO2000000481A1 (en) * 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
US6319937B1 (en) 1998-11-18 2001-11-20 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
US6303609B1 (en) 1998-11-18 2001-10-16 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5239113A (en) * 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof

Also Published As

Publication number Publication date
CA2174415A1 (en) 1995-06-01
WO1995014682A1 (en) 1995-06-01
JPH09505589A (ja) 1997-06-03
AU1097895A (en) 1995-06-13
EP0730589A1 (de) 1996-09-11
DE69411584T2 (de) 1998-12-17
DK0730589T3 (da) 1999-02-01
ATE168106T1 (de) 1998-07-15
AU677481B2 (en) 1997-04-24
EP0730589B1 (de) 1998-07-08
ES2120713T3 (es) 1998-11-01
NZ276631A (en) 1997-06-24

Similar Documents

Publication Publication Date Title
ATE198748T1 (de) Isoxazoline und isoxazole derivate als fibrinogen rezeptor antagonisten
PL323835A1 (en) Novel isoxazolinic and isoxazolic antagonists of fibrinogen receptor
DE69411584D1 (de) Isoxazoline derivate anwendbar als fibrinogen rezeptor antagonisten
ATE267011T1 (de) Isoxazolin, isothiazolin und pyrazolin als faktor xa inhibitoren
FI960727A (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
ATE178614T1 (de) Zyklische verbindungen zur verwendung als inhibitoren des glycoprotein iib/iiia
DK58291D0 (da) Krystalinsk stof og dets fremstilling
TR199700999T1 (xx) Askomisinler.
WO2005035495A3 (en) Fibrinogen receptor antagonists and their use
WO2000029406A3 (en) Novel isoxazoline fibrinogen receptor antagonists
ATE187956T1 (de) Substituierte kondensierte und verbrückte bicyclische verbindungen als therapeutische mittel
MX9709081A (es) Nuevos antagonistas del receptor fibrinogeno de isoxazolina e isoxazol.
NO933558L (no) Benzimidazoler, legemidler inneholdende disse forbindelser, og fremgangsmåte for deres fremstilling
DE69810332D1 (de) Antibakterielle carbapeneme, zusammensetzungen und verfahren zur behandlung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: DU PONT PHARMACEUTICALS CO., WILMINGTON, DEL., US

8327 Change in the person/name/address of the patent owner

Owner name: BRISTOL-MYERS SQUIBB PHARMA CO., PRINCETON, N.J.,

8339 Ceased/non-payment of the annual fee